Trouble in Botox-land?

Pharmaceuticals firm Allergan is not a maker of allergy medicines, as its name might imply. It’s a company catering to those who want to look, see, and feel better. What started off as an eye and skin-care treatment maker now gets a large chunk of its profit from Botox, the popular wrinkle-reducer used in cosmetic procedures. The company also makes breast implants and obesity treatment device Lap-Band.

Despite its obviously successful line of products catering to self-image shoppers, as well as eye and skin disease sufferers, Allergan has a few storms brewing on its front. Impending competition from rival Medicis, which is working to bring a Botox-like product to market, is at the fore. Several other companies have similar products in development stages.

Allergan has so far had a monopoly in the US anti-wrinkle drug market; Botox makes the company over $1 billion per year, or about one-third of Allergan‘s annual sales. The company is also facing an opponent in Johnson & Johnson, which plans to launch a product similar to the Lap-Band.

In addition, late last year the company filed a patent infringement suit against several personal care product makers, including Jan Marini Skin Research, for selling eyelash extending products that contain ingredients similar to Allergan‘s Lumigan, a prescription drug used to treat glaucoma. Rumor has it that Allergan is pursuing its own eyelash enhancement product based on the Lumigan formula, a move that follows in the footsteps of Botox, which started off as a medical treatment for facial muscle spasms.

Regardless of these roadblocks, many analysts and investors remain bullish about Allergan‘s stock. The company has a healthy pipeline and a wide berth of traditional pharmaceuticals in its stable to maintain sales, especially in the eye care field. In addition, the popularity of Botox – come on, we’ve all heard of it – is unlikely to suffer too much, especially with the ever-increasing popularity of cosmetic procedures. All in all, my estimation is that Allergan probably won’t feel more than a minor discomfort from the aforementioned threats.

Anne Law

Anne Law has been a member of the D&B editorial department for more than a decade, providing content for the Hoover's and First Research products. She currently covers the health care and insurance industries for First Research. For industry news, follow Anne on Twitter.

Read more articles by Anne Law.

Comments

  1. Thusfar the alternatives to Botox have had deliberately milder effects, Allergan is barely even under indirect threat.

Leave a Comment